The Almac Group has today announced the release of its 2024 Sustainability Report which outlines Almac’s ongoing commitment to their people, the planet and the communities where the Group operates, through sustainable practices, community engagement and ethical business operations.
One of Almac’s core objectives is to support, develop, and reward its global workforce of over 7,500 people. The group recently announced that each employee will receive an additional day of leave. This ‘Diversity Day’ can be used to celebrate diversity, to volunteer or take part in community work.
During the last year, Almac Group has supported 60 different charities through global philanthropy and reaching more than 17,000 post-primary pupils through in-person and virtual outreach programmes.
The transition to renewable energy has been a key part of Almac’s journey to net zero over the last year, having announced a virtual power purchase agreement (vPPA) with a wind farm to provide electricity for its Craigavon headquarters. 95% of the electricity consumed at Almac’s Craigavon campus comes from renewable sources, representing a 46% reduction in global scope 2 emissions.
In August 2024 Almac successfully completed the ISO 14064 -1 verification. This emphasises Almac’s dedication to environmental sustainability and transparency through accurate and reliable reporting of greenhouse gas (GHG) emissions.
The report also highlights that Almac is now zero waste to landfill in the facilities where 80% of employees are based.
Alan Armstrong, Chairman and CEO, Almac Group said: “As we support our partners in delivering life-saving medicines across the globe we are conscious of our impact on the people and world around us”
“The achievements in this report reflect Almac’s commitment to advancing human health through the work we do for our clients but also the part we play in ensuring a more sustainable future. The progress made towards our goals this year is thanks to the dedication of our people who I am truly honoured to work with each and every day.”
Read the full report here.
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically, now employing 7,500 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
To keep up to date with latest news, follow us on X and LinkedIn or visit almacgroup.com.
